Fulcrum Therapeutics (NASDAQ:FULC) delivers shareholders stellar 110% return over 1 year, surging 27% in the last week alone

Investing in stocks carries risks, but choosing the right stock can lead to significant returns. Fulcrum Therapeutics' stock price has surged 110% in a year, despite a 38% revenue decrease. Investors should consider various factors before investing in the company.